Marinus Pharmaceuticals: Q3 Earnings Snapshot
Check out these three micro-cap stocks that show big-time potential upside, but also pose face large obstacles to achieving success.
Marinus is an under $2 biotech stock with Wall Street analysts price targets ranging from $2 to $13. Its upcoming trial results have big implications.
Marinus Pharmaceuticals: Q2 Earnings Snapshot
Marinus Pharmaceuticals: Q1 Earnings Snapshot
Marinus Pharmaceuticals: Q4 Earnings Snapshot
Marinus Pharmaceuticals: Q3 Earnings Snapshot
Marinus Pharmaceuticals: Q2 Earnings Snapshot
Marinus Pharmaceuticals: Q1 Earnings Snapshot
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that management will present...